NASDAQ · Biotechnology

TLSA (TLSA) Stock

$1.03 +6.19% NASDAQ: TLSA Healthcare

Valuation

MetricValue
Price$1.03
Market Cap$65.54M
P/E Ratio-3.59
P/B Ratio20.52
P/S Ratio0.00
EPS (TTM)$-0.32
52-Week High$2.60
52-Week Low$0.89
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-9.24%
ROA-1.16%
ROCE—
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio0.82

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-37.0M$-18.0M$-23.0M$-16.0M$-21.0M
Net Profit$-32.0M$-19.0M$-22.0M$-12.0M$-18.0M
EPS$-0.64$-0.36$-0.42$-0.22$-0.32
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$49.0M$26.0M$12.0M$11.0M$11.0M
Total Liabilities$8.0M$7.0M$7.0M$7.0M$11.0M
Cash$42.0M$18.0M$1.0M$4.0M$4.0M
Borrowings$1.0M$0$0$0$0

Latest News

Sector Update: Healthcare Stocks Lower in Afternoon Trading MT Newswires · Jul 22, 2026 Tiziana Life Sciences Says Executive Chairman Gabriele Cerrone Boosts Stake MT Newswires · Jul 22, 2026 Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman GlobeNewswire · Jul 22, 2026 Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial Proactive · Jun 25, 2026 Tiziana Life Sciences Doses Last Patient in Phase 2 Trial of Potential Multiple Sclerosis Treatment MT Newswires · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-16.0M$-16.0M$-12.0M$-1.0M$-13.0M
Investing Cash Flow$0$-3.0M$-1.0M$0$3.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-18.0M$-20.0M$-13.0M$2.0M$0
Free Cash Flow$-16.0M$-16.0M$-12.0M$-1.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-17.77%
Quick Ratio8.79
Interest Coverage—
Return 1Y-22.11%
Return 3Y68.38%
Return 5Y-39.74%

Ownership

Insiders Held47.65%
Institutions Held3.20%
Institutions Float Held6.11%
Institutional HolderSharesReport Date
Dauntless Investment Group, LLC 2,165,2312026-03-31
Mid-american Wealth Advisory Group, Inc.323,2402026-06-30
Marshall Wace LLP157,5662026-03-31
Zhang Financial LLC111,9002026-03-31
UBS Group AG95,7002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANEBAnebulo Pharmaceuticals, Inc. $0.34 +0.00% -1.73 $13.72M 0.00%
COYA $4.00 -6.21% -2.62 $72.84M 0.00%
ESLAEstrella Immunopharma, Inc. $0.78 +0.06% -2.25 $33.59M 0.00%
EXOZ $4.65 +1.09% -8.62 $43.16M 0.00%
IMMX $8.55 +4.65% -9.96 $465.14M 0.00%

About TLSA

TLSA is led by CEO Ivor R. Elrifi, employs 9 people, headquartered in GB, publicly traded since 2018.

TLSA stock trades at $1.03 with a market capitalization of $65.54M. The stock is valued at a price-to-earnings (P/E) ratio of -3.59, price-to-book of 20.52, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.89 and $2.60, and currently trades 60.4% below its 52-week high.

On profitability, TLSA generates a return on equity (ROE) of -9.24%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides